Cover Image
市場調查報告書

多發性硬化症:流行病學、病患人數的市場預測,治療流程,已上市/開發平台藥物分析

Multiple sclerosis: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365215
出版日期 內容資訊 英文 339 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
多發性硬化症:流行病學、病患人數的市場預測,治療流程,已上市/開發平台藥物分析 Multiple sclerosis: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年01月01日 內容資訊: 英文 339 Pages
簡介

多發性硬化症的治療藥的市場可說是潛在市場規模很大,不過,正因為如此新加入企業和 (臨床實驗最後階段的) 開發平台候補藥等大量湧入市場,打算搶食現有企業/產品的市場佔有率,市場競爭變得非常激烈。

本報告提供多發性硬化症的已上市/臨床實驗中 (開發平台上)的治療藥相關分析,各產品的市場規模的估計值,新藥上市的市場規模的變動預測,及現在、未來的代表性產品,疾病的各種類 (亞型) 的詳細情況,醫生面臨的各種問題等相關調查。

市場預測:多發性硬化症

  • 摘要整理
  • 市場概要與趨勢
  • 市場定義和分析方法
  • Aubagio (teriflunomide)
  • Avonex (干擾素β-1a)
  • Betaseron/Betaferon (干擾素β-1b)
  • Copaxone (glatiramer acetate)
  • Extavia (干擾素β-1b)
  • Gilenya (Fingolimod)
  • Lemtrada (alemtuzumab)
  • Nerventra (laquinimod)
  • Ocrelizumab
  • ozanimod
  • Plegridy (PEG干擾素β-1a)
  • ponesimod
  • Rebif (干擾素β-1a)
  • siponimod
  • Tecfidera (富馬酸二甲酯)
  • Tysabri (natalizumab)
  • Zinbryta (daclizumab)
  • 一次調查技術

治療方法:多發性硬化症

  • 摘要整理
  • 一次調查技術
  • 疾病定義與診斷方法
  • 患者的分類
  • 各國治療系統
  • 目前治療選擇
  • 處方的趨勢
  • 多發性硬化症相關的未滿足需求

流行病學:多發性硬化症

  • 摘要整理
  • 疾病的背景情況
  • 全球各地的趨勢的差異
  • 風險要素
  • 資訊來源、分析方法
  • 市場預測
  • 流行病學者的見解
  • 分析的優勢與限制

已上市藥物:多發性硬化症

  • 摘要整理
  • 產品概要
  • 附錄
  • 產品簡介:Ampyra
  • 產品簡介:Aubagio
  • 產品簡介:Avonex
  • 產品簡介:Betaseron
  • 產品簡介:Copaxone
  • 產品簡介:Extavia
  • 產品簡介:Gilenya
  • 產品簡介:Lemtrada
  • 產品簡介:Plegridy
  • 產品簡介:Rebif
  • 產品簡介:Tecfidera
  • 產品簡介:Tysabri

開發中產品:多發性硬化症

  • 摘要整理
  • 臨床實驗開發平台概要
  • 附錄
  • 產品簡介 (最後階段):Nerventra
  • 產品簡介 (最後階段):Zinbryta
  • 產品簡介 (最後階段):Ocrelizumab
  • 產品簡介 (最後階段):ozanimod
  • 產品簡介 (最後階段):ponesimod
  • 產品簡介 (最後階段):siponimod

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC4810

Competition is mounting in the lucrative multiple sclerosis market, as new entrants and late-stage pipeline candidates look to capture market share from established players.

This report addresses the following questions:

  • How have oral disease-modifying therapies changed prescribing trends in multiple sclerosis - and how will they impact overall market sales?
  • What are the current leaders of the market-and how will these change by 2023?
  • What therapies are under development for progressive multiple sclerosis subtypes?
  • Which are the current treatment practices in multiple sclerosis, by disease subtype?
  • Which treatment challenges are physicians faced with?

TABLE OF CONTENTS

FORECAST: MULTIPLE SCLEROSIS

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. Aubagio (teriflunomide) ,
  • 5. Avonex (interferon beta-1a)
  • 6. Betaseron/Betaferon (interferon beta-1b)
  • 7. Copaxone (glatiramer acetate)
  • 8. Extavia (interferon beta-1b)
  • 9. Gilenya (fingolimod)
  • 10. Lemtrada (alemtuzumab)
  • 11. Nerventra (laquinimod)
  • 12. ocrelizumab
  • 13. ozanimod
  • 14. Plegridy (peginterferon beta-1a)
  • 15. ponesimod
  • 16. Rebif (interferon beta-1a)
  • 17. siponimod
  • 18. Tecfidera (dimethyl fumarate)
  • 19. Tysabri (natalizumab)
  • 20. Zinbryta (daclizumab)
  • 21. Primary Research Methodology

TREATMENT: MULTIPLE SCLEROSIS

  • 22. Executive Summary
  • 23. Primary Research Methodology
  • 24. Disease Definition and Diagnosis
  • 25. Patient Segmentation
  • 26. Country Treatment Trees
  • 27. Current Treatment Options
  • 28. Prescribing Trends
  • 29. Unmet Needs in Multiple Sclerosis

EPIDEMIOLOGY: MULTIPLE SCLEROSIS

  • 30. Executive Summary
  • 31. Disease Background
  • 32. Global Variations
  • 33. Risk Factors
  • 34. Sources and Methodology
  • 35. Forecast
  • 36. Epidemiologist Insight
  • 37. Strengths and Limitations

MARKETED DRUGS: MULTIPLE SCLEROSIS

  • 38. Executive Summary
  • 39. Product Overview
  • 40. Appendix
  • 41. Product profile: Ampyra
  • 42. Product profile: Aubagio
  • 43. Product profile: Avonex
  • 44. Product profile: Betaseron
  • 45. Product profile: Copaxone
  • 46. Product profile: Extavia
  • 47. Product profile:Gilenya
  • 48. Product profile: Lemtrada
  • 49. Product profile: Plegridy
  • 50. Product profile: Rebif
  • 51. Product profile: Tecfidera
  • 52. Product profile: Tysabri

PIPELINE: MULTIPLE SCLEROSIS

  • 53. Executive Summary
  • 54. Clinical Pipeline Overview
  • 55. Appendix
  • 56. Product profile (late stage): Nerventra
  • 57. Product profile (late stage): Zinbryta
  • 58. Product profile (late stage): ocrelizumab
  • 59. Product profile (late stage): ozanimod
  • 60. Product profile (late stage): ponesimod
  • 61. Product profile (late stage): siponimod
Back to Top